论文部分内容阅读
目的:探讨黄芪注射液辅助抗结核药治疗肺结核的临床疗效。方法:84例肺结核患者为研究对象,将所有患者根据入院顺序分为对照组和研究组,每组42例。对照组患者采用常规的抗结核药物治疗,研究组在其基础上联合应用黄芪注射液辅助治疗。对比两组患者的临床疗效。结果:研究组第一季度痰菌转阴率为92.86%,对照组第一季度痰菌转阴率为71.43%,两组比较差异具有统计学意义(P<0.05)。研究组空洞闭合率为80.95%,对照组空洞闭合率为61.90%,两组比较差异具有统计学意义(P<0.05)。结论:黄芪注射液辅助抗结核药能有效提高肺结核患者痰菌转阴率,减少空洞数量,具有重要的临床应用价值。
Objective: To investigate the clinical efficacy of astragalus injection assisted with anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Methods: Eighty-four patients with pulmonary tuberculosis were enrolled in this study. All patients were divided into control group and study group according to admission sequence, with 42 patients in each group. Patients in the control group were treated with conventional anti-tuberculosis drugs. The research group was adjuvant with Astragalus injection on the basis of the control group. Compare the clinical efficacy of two groups of patients. Results: In the first quarter of the study group, the negative rate of sputum bacterium was 92.86%. The negative rate of sputum bacterium in the first quarter of the control group was 71.43%. There was significant difference between the two groups (P <0.05). The void closure rate was 80.95% in the study group and 61.90% in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion: Astragalus injection adjuvant anti-TB drugs can effectively improve the rate of sputum bacilli in patients with pulmonary tuberculosis, reduce the number of cavities, has important clinical value.